KYORIN Pharmaceutical Co.,Ltd.
Notice Concerning Change in Major Shareholder
Filed with TSE ·
6ix is reading this filing.
View original source (TDnet)KYORIN Pharmaceutical Co.,Ltd. on 6ix
Earlier from KYORIN Pharmaceutical Co.,Ltd
- (Update on Disclosed Matter) Notice Regarding Transfer of Generic Drug Business
- KYORIN to Commence Promotion Activities for Allergic Conjunctivitis Treatment Alesion Eyelid Cream 0.5%
- [Summary]Consolidated Financial Results for the Three Months Ended June 30, 2026 [Japanese GAAP]
- KYORIN Entered into Joint Marketing Agreement in Japan for Allergic Conjunctivitis Treatment Alesion Eyelid Cream 0.5%
- KYORIN Pharmaceutical: Operating profit fell 71.6% year-over-year as sales declined and R&D costs rose
Follow KYORIN Pharmaceutical Co.,Ltd into a list and get an email when it puts out news.
Follow KYORIN Pharmaceutical Co.,Ltd